Education
About Us
Working with TipRanks
Follow Us
Orasure Technologies (OSUR)
NASDAQ:OSUR
Top Page
Orasure Technologies
(NASDAQ:OSUR)
Rating:52Neutral
Price Target:
$3.00
▲(6.76%Upside)
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$216.92M
Dividend YieldN/A
Average Volume (3M)632.13K
Price to Earnings (P/E)25.3
Beta (1Y)0.60
Revenue Growth-46.95%
EPS Growth-237.44%
CountryUS
Employees501
SectorHealthcare
Sector Strength41
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.21
Shares Outstanding74,800,130
10 Day Avg. Volume731,511
30 Day Avg. Volume632,127
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio7.96
Enterprise Value/Market Cap-0.30
Enterprise Value/Revenue-0.07
Enterprise Value/Gross Profit-0.81
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$3.00Price Target Upside6.76% Upside
Rating ConsensusHold
Number of Analyst Covering1
Orasure Technologies Business Overview & Revenue Model
Company DescriptionOraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
How the Company Makes MoneyOraSure Technologies generates revenue through the sale of its diagnostic products and specimen collection devices. The company's primary revenue streams include sales of rapid diagnostic tests for infectious diseases, such as HIV and hepatitis C, and its oral fluid collection systems used in various testing applications. Orasure also earns income from its laboratory services, which provide diagnostic testing and analysis. Significant partnerships with governmental and non-governmental organizations, healthcare providers, and research institutions contribute to its earnings by facilitating the distribution and adoption of its diagnostic solutions. Additionally, the company benefits from strategic collaborations and licensing agreements that enhance its market reach and product development capabilities.
Orasure Technologies Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q1-2025)
| % Change Since: 0.72%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments and challenges. While the company reported strong diagnostics revenue growth and successful integration of Sherlock Biosciences, it faced significant headwinds from funding uncertainties and disruptions in the Sample Management Solutions segment. The overall sentiment is balanced with positive steps towards innovation and growth, countered by challenges in funding and customer disruptions.Q1-2025 Updates
Positive Updates
Core Revenue Performance
Q1 core revenue was $29.5 million, above the midpoint of the guidance range, and flat year-over-year after adjusting for the exit from the risk assessment testing business.
Diagnostics Revenue Growth
Diagnostics revenue grew 8% year-over-year, driven by international business and initial orders for WHO PQ listed hepatitis C self-test.
Successful Integration of Sherlock Biosciences
Integration of Sherlock Biosciences is progressing well, contributing to OTI's product pipeline with molecular diagnostics innovation.
Stock Repurchase Program
Board authorized the repurchase of up to $40 million of common stock over the next two years, funded from cash on hand.
International Business Stability
International Diagnostics business remains steady despite funding uncertainties, with growth driven by hepatitis C self-test orders.
New Product Launches
Planned product launches include microbiome extraction kits, blood proteomics sample stabilization, and entrance into the small volume self-collected blood segment.
Negative Updates
Sample Management Solutions Revenue Decline
SMS revenue decreased 16% year-over-year due to disruption at a large customer in the Consumer Genomics segment.
U.S. Diagnostics Headwinds
Elevated uncertainty in the U.S. due to potential budget cuts and staffing reductions at public health organizations.
PEPFAR and USAID Funding Disruption
Disruption in USAID and PEPFAR sponsored programs contributed to revenue headwinds, although less severe than initially expected.
Together Take Me Home Program Ending
The program is scheduled to end in September 2025 due to funding impacts, contributing to a $4 million revenue headwind for the year.
Uncertain Consumer Genomics Partnership
Significant disruption from a major consumer genomics customer with no expected revenue in Q2 and uncertain future ordering potential.
Company Guidance
During the OraSure Technologies 2025 First Quarter Earnings Call, the company provided guidance for the second quarter, projecting total revenue of $28.5 million to $32.5 million and core revenue of $28 million to $32 million, excluding COVID-19 and risk assessment testing revenues, which are expected to contribute approximately $5 million. The company anticipates its gross margin percentage to be flat or slightly up compared to the first quarter, with potential expansion in the second half of the year driven by increased volumes and efficiencies from automation and site consolidation. Operating expenses in Q2 are expected to include core expenses in the low $20 million range, plus $10 million in innovation investments, of which $7 million to $8 million are related to the Sherlock acquisition. The company also announced a $40 million stock repurchase program over the next two years, funded from cash on hand, aligning with their capital deployment strategy.Orasure Technologies Financial Statement Overview
Summary
Orasure Technologies is facing operational challenges with a significant decline in revenue and profitability. Despite a strong balance sheet with low leverage and high equity, cash flow issues and negative net income highlight the need for strategic adjustments to improve operational efficiency and return to profitability.Income Statement
Orasure Technologies has experienced a significant decline in total revenue from $405.47 million in 2023 to $185.83 million in 2024, a decrease of 54.15%. The gross profit margin has improved significantly, likely due to reduced revenue reporting errors ($78.36 million gross profit on $185.83 million revenue), but the company is operating at a loss with a negative EBIT and net income. This indicates challenges in profitability and operational efficiency.45
Neutral
Balance Sheet
The company's balance sheet is relatively strong with a high equity ratio of 85.57% and low debt levels, as evidenced by a debt-to-equity ratio of 0.04. Stockholders' equity is solid, but the decrease in total assets over the year suggests potential concerns about asset utilization. Nevertheless, the company's low leverage and strong equity position are positive indicators of financial stability.70
Positive
Cash Flow
The operating cash flow has drastically decreased from $141.58 million in 2023 to $27.37 million in 2024, indicating challenges in generating cash from operations. However, the company has maintained positive free cash flow, albeit significantly lower than the previous year. The free cash flow to net income ratio indicates cash inefficiency, as the net income is negative.55
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 185.83M | 405.47M | 387.48M | 233.67M | 171.72M | Gross Profit |
| 76.23M | 179.42M | 147.64M | 117.60M | 101.87M | EBIT |
| -28.25M | 32.68M | -4.67M | -11.65M | -6.28M | EBITDA |
| -13.55M | 64.35M | 10.29M | 9.00K | 3.44M | Net Income Common Stockholders |
| -19.50M | 53.66M | -17.93M | -23.00M | -14.92M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 267.76M | 290.41M | 110.85M | 153.04M | 209.40M | Total Assets |
| 479.66M | 482.85M | 444.71M | 460.99M | 454.47M | Total Debt |
| 14.60M | 13.50M | 12.55M | 12.27M | 6.13M | Net Debt |
| -253.16M | -276.90M | -71.43M | -104.49M | -154.67M | Total Liabilities |
| 69.32M | 52.17M | 81.08M | 80.46M | 55.90M | Stockholders Equity |
| 410.34M | 430.67M | 363.62M | 380.53M | 398.57M |
| Cash Flow | Free Cash Flow | |||
| 23.58M | 131.28M | -111.11M | -83.50M | -23.12M | Operating Cash Flow |
| 27.37M | 141.58M | -47.20M | -35.38M | 5.81M | Investing Cash Flow |
| -39.03M | 66.15M | 21.09M | -5.50M | -14.03M | Financing Cash Flow |
| -4.18M | -3.02M | -3.83M | -2.82M | 92.48M |
Orasure Technologies Technical Analysis
Neutral
2.81
Price Trends
2.91
Negative
3.31
Negative
3.69
Negative
Market Momentum
>-0.01
Negative
50.26
Neutral
77.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Neutral. The current price of 2.81 is above the 20-day moving average (MA) of 2.68, below the 50-day MA of 2.91, and below the 200-day MA of 3.69, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.26 is Neutral, neither overbought nor oversold. The STOCH value of 77.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We May Fail to Realize the Anticipated Benefits of the Acquisition of Sherlock. Q4, 2024
2.
The Use of New And Evolving Technologies, Such As Artificial Intelligence ("AI"), In Our Offerings May Present Risks And Challenges That Can Impact Our Business Including by Posing Security Risks to Our Confidential Information, Proprietary Information, and Personal Data. Q4, 2024
3.
The Increasing Prevalence of AI-based Software Presents New Risks and Could Adversely Affect Our Business and Reputation. Q4, 2024
Orasure Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $181.90M | 14.83 | 10.59% | 2.16% | -19.92% | ― | |
64 Neutral | $196.94M | ― | -179.82% | ― | 1.50% | -20.00% | |
63 Neutral | $139.52M | 14.74 | 28.29% | ― | 29.65% | 131.78% | |
61 Neutral | $131.04M | ― | -29.87% | ― | 19.65% | 60.28% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
52 Neutral | $216.92M | 25.27 | -7.77% | ― | -46.95% | -237.44% | |
50 Neutral | $260.41M | ― | -28.58% | ― | 34.65% | -128.56% |
* Healthcare Sector Average
Performance Comparison
OSUR
Orasure Technologies
2.81
-2.03
-41.94%
PDEX
Pro-Dex
42.23
22.48
113.82%
STXS
Stereotaxis
2.24
0.26
13.13%
UTMD
Utah Medical Products
56.04
-10.01
-15.16%
KRMD
REPRO-MED Systems
2.92
0.63
27.51%
SMTI
Sanara MedTech
28.88
-0.33
-1.13%
Orasure Technologies Corporate Events
Shareholder MeetingsBusiness Operations and Strategy
OraSure Technologies Approves Stock Plan Amendment at Annual Meeting
Neutral
May 14, 2025
On May 14, 2025, OraSure Technologies, Inc. held its Annual Meeting of Stockholders, where an amendment to the 2000 Stock Award Plan was approved, increasing the number of shares authorized for grant by 6,000,000 shares. The meeting also included the election of three Class I Directors, the ratification of Grant Thornton LLP as the independent registered public accounting firm for 2025, and an advisory vote on executive compensation, reflecting key governance and operational decisions impacting the company’s future direction.
The most recent analyst rating on (OSUR) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
Executive/Board ChangesBusiness Operations and Strategy
OraSure Technologies Announces CPO Resignation
Neutral
May 9, 2025
On May 8, 2025, Kathleen G. Weber announced her resignation as Chief Product Officer of OraSure Technologies, effective June 30, 2025. Her resignation, considered as ‘Good Reason,’ entitles her to severance benefits as per her employment agreement. This change in leadership may impact the company’s operations and strategic direction.
Stock BuybackBusiness Operations and StrategyFinancial Disclosures
OraSure Technologies Reports Q1 2025 Revenue Decline
Negative
May 7, 2025
On May 7, 2025, OraSure Technologies announced its financial results for the first quarter of 2025, revealing a 45% decrease in total net revenues compared to the same period in 2024, primarily due to a decline in COVID-19 revenues. Despite the revenue drop, the company is focusing on expanding its product portfolio and strengthening customer relationships, with a $40 million stock repurchase program authorized to deliver shareholder value.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.